Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.